medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 5

<< Back Next >>

Rev Invest Clin 2012; 64 (5)

Toll-like receptors in development and function of the hematopoietic system

Vadillo E, Pelayo R

Language: Spanish
References: 111
Page: 461-476
PDF size: 401.27 Kb.


ABSTRACT

Virus, bacteria, fungi and parasites are pathogens to which individuals are constantly exposed. Pathogen recognition by cells of the immune system is carried out by a growing list of pattern-recognition receptors (PRRs) which are evolutionally conserved and absent in mammals, named pathogenassociated molecular patterns (PAMPs). PRRs can be found in extracellular matrix, within cytoplasm and on cellular membranes. Among the membrane PRRs, Toll-like receptors (TLRs) induce the production of pro-inflammatory cytokines and the expression of co-stimulatory molecules upon stimulation on mature cells, resulting in the triggering of immune danger signals. Recent reports showing the regulation of hematopoiesis by TLRs, suggest that they are involved in the most primitive stages of hematopoietic development and contribute to emergent replenishment of innate immune cells. These data entail TLRs to hematopoiesis and also revolutionize our understanding of the mechanisms governing infection responses. In this review, we focus on the most relevant findings from the TLR discovery to the use of TLR agonists and antagonists in novel therapies for infectious, autoimmune and neoplastic diseases. Of special interest is the research progress in the TLR functional expression by primitive hematopoietic stem and progenitor cells.


REFERENCES

  1. Mayani H. A glance into somatic stem cell biology: basic principles, new concepts, and clinical relevance. Arch Med Res 2003; 34: 3-15.

  2. Marsh JC, Boggs DR, Cartwright GE, et al. Neutrophil kinetics in acute infection. J Clin Invest 1967; 46: 1943-53.

  3. Anderson KV, Jurgens G, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 1985; 42: 779-89.

  4. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010.

  5. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442: 39-44.

  6. Lee MS, Kim YJ. Pattern-recognition receptor signaling initiated from extracellular, membrane, and cytoplasmic space. Mol Cells 2007; 23: 1-10.

  7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.

  8. Levashina EA, Langley E, Green C, et al. Constitutive activation of toll-mediated antifungal defense in serpin-deficient Drosophila. Science 1999; 285: 1917-9.

  9. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.

  10. McGettrick AF, O’Neill LA. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 2007; 139: 185-93.

  11. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-83.

  12. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.

  13. Travis J. Nobel Prize in physiology or medicine. Immunology prize overshadowed by untimely death of awardee. Science 2011; 334: 31.

  14. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32: 305-15.

  15. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8: 594-606.

  16. Arancibia SA, Beltran CJ, Aguirre IM, et al. Toll-like receptors are key participants in innate immune responses. Biol Res 2007; 40: 97-112.

  17. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-33.

  18. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-80.

  19. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.

  20. Funderburg N, Lederman MM, Feng Z, et al. Human-defensin- 3 activates professional antigen-presenting cells via Tolllike receptors 1 and 2. Proc Natl Acad Sci USA 2007; 104: 18631-5.

  21. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57-63.

  22. Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003; 4: 1247-53.

  23. Andersen-Nissen E, Smith KD, Strobe KL, et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci USA 2005; 102: 9247-52.

  24. Kariko K, Ni H, Capodici J, et al. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279: 12542-50.

  25. Mancuso G, Gambuzza M, Midiri A, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009; 10: 587-94.

  26. Baltimore D, Boldin MP, O’Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9: 839-45.

  27. Wagner H. Hemozoin: malaria’s «built-in» adjuvant and TLR9 agonist. Cell Host Microbe 2010; 7: 5-6.

  28. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin- IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-7.

  29. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174: 2942-50.

  30. Nyman T, Stenmark P, Flodin S, et al. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem 2008; 283: 11861-5.

  31. Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24: 801-12.

  32. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-5.

  33. Lord KA, Abdollahi A, Hoffman-Liebermann B, et al. Dissection of the immediate early response of myeloid leukemia cells to terminal differentiation and growth inhibitory stimuli. Cell Growth Differ 1990; 1: 637-45.

  34. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.

  35. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-50.

  36. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9: 143-50.

  37. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature 2009; 458: 430-7.

  38. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-61.

  39. Hasan UA, Caux C, Perrot I, et al. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci USA 2007; 104: 8047-52.

  40. Burns K, Janssens S, Brissoni B, et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003; 197: 263-8.

  41. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.

  42. Welner RS, Pelayo R, Garrett KP, et al. Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors. Blood 2007; 109: 4825-931.

  43. Pelayo R, Hirose J, Huang J, et al. Derivation of 2 categories of plasmacytoid dendritic cells in murine bone marrow. Blood 2005; 105: 4407-15.

  44. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997; 91: 661-72.

  45. Hardy RR, Kincade PW, Dorshkind K. The protean nature of cells in the B lymphocyte lineage. Immunity 2007; 26: 703-14.

  46. Akashi K, Traver D, Miyamoto T, et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-7.

  47. Welner RS, Pelayo R, Nagai Y, et al. Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection. Blood 2008; 112: 3753-61.

  48. Downes JE, Marshall-Clarke S. Innate immune stimuli modulate bone marrow-derived dendritic cell production in vitro by toll-like receptor-dependent and -independent mechanisms. Immunology 2010; 131: 513-24.

  49. Schmid MA, Takizawa H, Baumjohann DR, et al. Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes. Blood 2011; 118: 4829-40.

  50. Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011; 32: 57-65.

  51. Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011; 186: 5367-75.

  52. Yanez A, Flores A, Murciano C, et al. Signalling through TLR2/MyD88 induces differentiation of murine bone marrow stem and progenitor cells to functional phagocytes in response to Candida albicans. Cell Microbiol 2010; 12: 114-28.

  53. Yanez A, Murciano C, O’Connor JE, et al. Candida albicans triggers proliferation and differentiation of hematopoietic stem and progenitor cells by a MyD88-dependent signaling. Microbes Infect 2009; 11: 531-5.

  54. Yanez A, Megias J, O’Connor JE, et al. Candida albicans Induces Selective Development of Macrophages and Monocyte Derived Dendritic Cells by a TLR2 Dependent Signalling. PLoS One 2011; 6: e24761.

  55. Basu S, Hodgson G, Zhang HH, et al. «Emergency» granulopoiesis in G-CSF-deficient mice in response to Candida albicans infection. Blood 2000; 95: 3725-33.

  56. Schwarz BA, Sambandam A, Maillard I, et al. Selective thymus settling regulated by cytokine and chemokine receptors. J Immunol 2007; 178: 2008-17.

  57. Zlotoff DA, Sambandam A, Logan TD, et al. CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus. Blood 2010; 115: 1897-905.

  58. Shi X, Zhang P, Sempowski GD, et al. Thymopoietic and bone marrow response to murine Pneumocystis pneumonia. Infect Immun 2011; 79: 2031-42.

  59. Lee SH, Hong B, Sharabi A, et al. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells 2009; 27: 1604-15.

  60. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, et al. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008; 112: 2205-13.

  61. Richard K, Pierce SK, Song W. The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J Immunol 2008; 181: 1746-52.

  62. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005; 17: 230-6.

  63. Jegerlehner A, Maurer P, Bessa J, et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007; 178: 2415-20.

  64. Hinton HJ, Jegerlehner A, Bachmann MF. Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr Top Microbiol Immunol 2008; 319: 1-15.

  65. Hayashi EA, Akira S, Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol 2005; 174: 6639-47.

  66. Gelman AE, Zhang J, Choi Y, et al. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004; 172: 6065-73.

  67. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007; 19: 39-45.

  68. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116: 485-94.

  69. Crellin NK, Garcia RV, Hadisfar O, et al. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 2005; 175: 8051-9.

  70. Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309: 1380-4.

  71. Chen Q, Davidson TS, Huter EN, et al. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J Immunol 2009; 183: 4458-6.

  72. Doulatov S, Notta F, Eppert K, et al. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 2010; 11: 585-93.

  73. Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med 2010; 2: 640-53.

  74. Mirandola P, Secchiero P, Pierpaoli S, et al. Infection of CD34(+) hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood 2000; 96: 126-31.

  75. Kim JM, Kim NI, Oh YK, et al. CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-kappaB-independent pathways. Int Immunol 2005; 17: 1525-31.

  76. Sioud M, Floisand Y, Forfang L, et al. Signaling through tolllike receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage. J Mol Biol 2006; 364: 945-54.

  77. Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 2007; 37: 2834-46.

  78. De Luca K, Frances-Duvert V, Asensio MJ, et al. The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia 2009; 23: 2063-74.

  79. Liu J, Guo YM, Hirokawa M, et al. A synthetic double-stranded RNA, poly I:C, induces a rapid apoptosis of human CD34(+) cells. Exp Hematol 2012; 40: 330-41.

  80. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101: 4500-04.

  81. Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 2011; 31: 89-98.

  82. Caron G, Duluc D, Fremaux I, et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005; 175: 1551-7.

  83. Komai-Koma M, Jones L, Ogg GS, et al. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 2004; 101: 3029-34.

  84. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008; 57: 1271-8.

  85. Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int Immunopharmacol 2006; 6: 863-9.

  86. Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 507-16.

  87. Uematsu S, Sato S, Yamamoto M, et al. Interleukin-1 receptorassociated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med 2005; 201: 915-23.

  88. Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 286-95.

  89. Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005; 77: 378-87.

  90. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007; 21: 53-60.

  91. Schmitt A, Li L, Giannopoulos K, et al. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 2008; 48: 861-70.

  92. Smits EL, Cools N, Lion E, et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother 2010; 59: 35-46.

  93. Tamaki Y, Takakubo Y, Hirayama T, et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 2011; 38: 810-20.

  94. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005; 52: 2313-22.

  95. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-C924.

  96. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-21.

  97. Xu J, Zhang X, Monestier M, et al. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol 2011; 187: 2626-31.

  98. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis as an Inflammatory Disease. Curr Pharm Des 2012.

  99. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007; 67: 4346-52.

  100. Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20: 1130-7.

  101. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20: 1138-44.

  102. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009; 1: 949-64.

  103. Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-9.

  104. Makkouk A, Abdelnoor AM. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 2009; 31: 331-8.

  105. Gawchik SM, Saccar CL. Pollinex Quattro Tree: allergy vaccine. Expert Opin Biol Ther 2009; 9: 377-82.

  106. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.

  107. Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9: 293-307.

  108. Dunne A, Marshall NA, Mills KH. TLR based therapeutics. Curr Opin Pharmacol 2011; 11: 404-11.

  109. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31: 520-7.

  110. Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002; 1: 797-807.

  111. O’Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-97.




2020     |     www.medigraphic.com